Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes

Annals of Internal Medicine

Volumn 133, Issue 4, 2000, Pages 263-274

  Arioglu, E ^a   Duncan Morin, J ^a   Sebring, N ^a   Rother, K I ^a   Gottlieb, N ^a   Lieberman, J ^a   Herion, D ^a   Kleiner, D E ^a   Reynolds, J ^a   Premkumar, A ^a   Sumner, A E ^a   Hoofnagle, J ^a   Reitman, M L ^a   Taylor, S I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRIACYLGLYCEROL; TROGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIPODYSTROPHY; LIVER BIOPSY; LIVER TOXICITY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034663140     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-4-200008150-00009     Document Type: Article

References (54)

1. Insulin resistance: The clinical spectrum
2. Generalized lipodystrophy, congenital and acquired (lipoatrophy)
3. The lipodystrophies and other rare disorders of the adipose tissue
4. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
5. Troglitazone action is independent of adipose tissue
6. Life without white fat: A transgenic mouse
7. Syndromes associated with insulin resistance and acanthosis nigricans
8. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
9. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34
10. Monogenic disorders of obesity and body fat distribution
11. Partial lipodystrophy associated with juvenile dermatomyositis: Report of two cases
12. Thiazolidinediones
13. Adipogenesis and obesity: Rounding out the big picture
14. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
15. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
16. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
17. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
18. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
19. Rosiglitazone for type 2 diabetes mellitus
20. Hepatocellular injury in a patient receiving rosiglitazone. A case report
21. Familial lipoatrophic diabetes with dominant transmission. A new syndrome
22. Mutational and haplotype analyses in families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C
23. Comparison of diabetes diagnostic categories in the U.S. population according to the 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria
24. Metabolic differences and the development of obesity
25. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire
26. The relationship in African-Americans of sex differences in insulin-mediated suppression of nonesterified fatty acids to sex differences in fasting triglyceride levels
27. Indirect calorimetry
28. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years
29. Body composition in children: Proposal for a method for calculating body fat percentage from total body density or skinfold-thickness measurements
30. Assessment of the composition of major body regions by dual-energy x-ray absorptiometry (DEXA), with special reference to limb muscle mass
31. Estimation of adipose tissue mass by magnetic resonance imaging: Validation against dissection in human cadavers
32. Theory and validity of indirect calorimetry during net lipid synthesis
33. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
35. Triglyceride as a risk factor for coronary artery disease
36. Diabetic dyslipidemia
37. Obesity and insulin resistance: Lessons learned from the Pima Indians
38. Recent update on the PPAR alpha-null mouse
39. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice
40. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
41. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
42. Effect of troglitazone on body fat distribution in type 2 diabetic patients
43. Effect of troglitazone in type 2 diabetes mellitus
44. Human peroxisome proliferator-activated receptor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes
45. No coding mutations are detected in the peroxisome proliferator-activated receptor-gamma gene in Japanese patients with lipoatrophic diabetes
46. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21-22
47. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
48. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
49. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
50. Fatal hepatotoxicity associated with troglitazone
51. An autopsy case of troglitazone-induced fulminant hepatitis
52. Isoniazid-related hepatitis
53. Rosiglitazone and hepatic failure